News - Lucentis, Markets & Marketing


Popular Filters

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments


Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report


Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads


The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis


USA-based pSivida Corp (Nasdaq: PSDV), a leader in developing sustained release, drug delivery products…

Alimera SciencesIluvienLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalpSividaResearch

Global orphan drugs market led by Roche's rituximab


The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe


Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report


After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

US retinal therapeutics market buoyant, says F&S


Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering…

AvastinGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRoche

Regeneron and Bayer’s Eylea backed by thought leaders for DME


Based on clinical data and the opinions of interviewed thought leaders by health care advisory firm Decision…

AllerganBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsOzurdexPharmaceuticalRegeneron

Drug approval and launch for Novartis in China, where Quintiles expands


Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State…

Asia-PacificDiabetesGalvusLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalQuintilesRegulationResearch

UK’s NICE unable to recommend Novartis Lucentis for diabetic macular edema; Fluvirin shipments begin in USA


The UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE) has issued…

EuropeFluvirinLucentisMarkets & MarketingNorth AmericaNovartisOphthalmicsPharmaceuticalPricingRegulationVaccines

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top